Drug-drug interactions between ketoconazole and Berberine in rats: Pharmacokinetic effects benefit pharmacodynamic synergism

Phytotherapy Research

Volumn 26, Issue 5, 2012, Pages 772-777

  Zhou, Yanmi ^a   He, Ping ^b   Liu, Aiming ^c   Zhang, Lixin ^d   Liu, Yunde ^b   Dai, Renke ^a,c  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c Zhongshan Pharmass Corporation   (China)

^d INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

berberine; drug drug interactions; ketoconazole; pharmacokinetic

Indexed keywords

BERBERINE; KETOCONAZOLE;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BERBERINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG SYNERGISM; FEMALE; KETOCONAZOLE; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; SPECIFIC PATHOGEN-FREE ORGANISMS; TANDEM MASS SPECTROMETRY;

RATTUS;

EID: 84859916900     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3621     Document Type: Article

References (25)

1. Ficker CE, Arnason JT, Vindas PS, et al,. 2003. Inhibition of human pathogenic fungi by ethnobotanically selected plant extracts. Mycoses 46: 29-37. (Pubitemid 36278897)
2. Findor JA, Sorda JA, Igartua EB, Avagnina A,. 1998. Ketoconazole-induced liver damage. Medicina (B Aires) 58: 277-281. (Pubitemid 28334578)
3. Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH,. 1999. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 48: 847-852.
4. Gellen-Dautremer J, Lanternier F, Dannaoui E, Lortholary O,. 2010. Antifungal combination therapy in invasive fungal infections. Rev Med Interne 31: 72-81. [In French.]
5. Gerntholtz T, Pascoe MD, Botha JF, Halkett J, Kahn D,. 2004. The use of a cyclosporin-ketoconazole combination: making renal transplantation affordable in developing countries. Eur J Clin Pharmacol 60: 143-148. (Pubitemid 38757123)
6. Graybill JR, Williams DM, Van Cutsem E, Drutz DJ,. 1980. Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis 2: 551-558.
7. Guengerich FP,. 1995. Cytochrome P450 proteins and potential utilization in biodegradation. Environ Health Perspect 103 (Suppl 5): 25-28.
8. Han Y, Lee JH,. 2005. Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol Pharm Bull 28: 541-544. (Pubitemid 40879986)
9. Huang Q, Wang GJ, Sun JG, Hu XL, Lu YH, Zhang Q,. 2007. Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 21: 1009-1018. (Pubitemid 46426822)
10. Hutson JL, Higgins JA,. 1987. Reversible activation inactivation of the deacylation acylation cycle in rat-liver mivrosomes. Biosci Rep 7: 73-80.
11. Iwazaki RS, Endo EH, Ueda-Nakamura T, Nakamura CV, Garcia LB, Filho BP,. 2010. In vitro antifungal activity of the berberine and its synergism with fluconazole. Antonie Van Leeuwenhoek 97: 201-205.
12. Liu Y, Hao H, Xie H, Lv H, Liu C, Wang G,. 2009. Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. J Pharm Sci 98: 4391-4401.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ,. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275.
14. Mantena SK, Sharma SD, Katiyar SK,. 2006. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 5: 296-308.
15. Nath A, Atkins WM,. 2006. A theoretical validation of the substrate depletion approach to determining kinetic parameters. Drug Metab Dispos 34: 1433-1435. (Pubitemid 44285381)
16. Qiu W, Jiang XH, Liu CX, Ju Y, Jin JX,. 2009. Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. Phytother Res 23: 1553-1558.
17. Rodriguez RJ, Acosta D, Jr. , 1997. N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 117: 123-131. (Pubitemid 27087486)
18. Rodriguez RJ, Proteau PJ, Marquez BL, Hetherington CL, Buckholz CJ, O'Connell KL,. 1999. Flavin-containing monooxygenase-mediated metabolism of N-deacetyl ketoconazole by rat hepatic microsomes. Drug Metab Dispos 27: 880-886. (Pubitemid 29347587)
19. Rukayadi Y, Lee K, Lee MS, Yong D, Hwang JK,. 2009. Synergistic anticandidal activity of xanthorrhizol in combination with ketoconazole or amphotericin B. FEMS Yeast Res 9: 1302-1311.
20. Sabra R, Branch RA,. 1990. Amphotericin B nephrotoxicity. Drug Saf 5: 94-108. (Pubitemid 20160824)
21. Shao LC, Sheng CQ, Zhang WN,. 2007. Recent advances in the study of antifungal lead compounds with new chemical scaffolds. Acta Pharmacol Sin 42: 1129-1136.
22. Shin S, Lim S,. 2004. Antifungal effects of herbal essential oils alone and in combination with ketoconazole against Trichophyton spp. J Appl Microbiol 97: 1289-1296. (Pubitemid 39573953)
23. Uno J, Shigematsu ML, Arai T,. 1983. Novel synergism of two antifungal agents, copiamycin and imidazole. Antimicrob Agents Chemother 24: 552-559. (Pubitemid 13021434)
24. US Food and Drug Administration. 2001. Guidance for Industry- Bioanalytical Method Validation. Washington, DC.
25. Zhang L, Yan K, Zhang Y, et al,. 2007. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc Natl Acad Sci USA 104: 4606-4611. (Pubitemid 47186272)